Clinical trial
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
NCT00174967 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00174967 |
|---|---|
| Title | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout |
| Official title | Phase II, Dose-Response, Safety and Efficacy Study of Oral TMX-67 in Subjects With Gout. |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gout |
| Intervention type | Drug |
| Interventions | Placebo, Febuxostat |
| Enrollment | 153 |
| Start date | Jan 1, 2001 |
| Primary completion | Jul 1, 2001 |
| Completion | Jul 1, 2001 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 29, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: